Although the United Kingdom’s gradual departure from the European Union included a transition period from February to December 2020, providing government agencies and businesses with ample time to adapt to the new reality, the shift to a new UK regulatory framework and pharmacovigilance protocols has continued to pose significant challenges in highly regulated industries like the veterinary pharmaceutical sector. Despite the new regulations being in force, the evidence on the ground suggests that both EU and UK businesses are still facing complexities in areas such as product registration, compliance with new licensing requirements.
Instead of one cohesive system, companies now have to navigate two distinct regulatory landscapes to be compliant with pharmacovigilance requirements. This article will unravel the current challenges in the post-Brexit UK for EU Veterinary Marketing Authorisation Holders (MAH) with a focus on the new measures and steps these businesses have to take to operate in the UK market and remain compliant.